Ramon Berrios, MD
Ophthalmology · Guaynabo, PRNPI 1407859820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 39.2% of the total. Reporting peaked in 2019 at $918 and has fallen 65.0% since, to $321 in 2025.
Across 39 payments — averaging $62.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$958
- Alcon Puerto Rico Inc$533
- Bausch & Lomb Americas Inc.$287
- Bausch & Lomb, A Division Of Bausch Health US, LLC$203
- Alcon$170
- Mallinckrodt Hospital Products Inc.$125
- plus $165 from 2 others
What the payments were for
- Food & beverage$2,42499%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $958 |
| Alcon Puerto Rico Inc | 5 | $533 |
| Bausch & Lomb Americas Inc. | 5 | $287 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $203 |
| Alcon | 2 | $170 |
| Mallinckrodt Hospital Products Inc. | 1 | $125 |
| Novartis | 2 | $122 |
| Sight Sciences, Inc. | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$360
- LUMIGAN$342
- ACTHAR$125
- MIEBO$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- Rhopressa$118
- Rocklatan$118
- COMBIGAN$116
- VYZULTA$108
- TRAVATAN Z$105
- Clareon$104
- LOTEMAX SM$100
How this compares
$2,442 in reported general payments places this provider in the 80th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 1,172 | $321,106 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 307 | $64,301 |
| AzoptBrinzolamide | 117 | $43,531 |
| Brimonidine Tartrate | 262 | $26,411 |
| Alphagan PBrimonidine Tartrate | 111 | $25,590 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 151 | $23,973 |
| Travoprost | 202 | $23,289 |
| RestasisCyclosporine | 35 | $22,713 |
| Brinzolamide | 101 | $16,790 |
| Latanoprost | 1,108 | $15,355 |
| CombiganBrimonidine Tartrate/Timolol | 53 | $10,970 |
| Prednisolone Acetate | 269 | $10,561 |
| Timolol Maleate | 361 | $10,105 |
| XiidraLifitegrast | 13 | $9,233 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 267 | $8,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $958 | $380,3781,371 claims |
| AlconSimbrinza, Azopt | $170 | $107,831424 claims |
| Bausch & Lomb Americas Inc.Xiidra | $287 | $9,23313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Guaynabo
- Wandsy VelezGuaynabo$6K
- Carlos PouGuaynabo$3K
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Armando OliverRio Piedras$251K
- Andres Emanuelli AnzalottaCorozal$50K
- Cristobal Cruz-ColonPonce$44K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.